Total arch replacement for an aortic arch aneurysm with cold agglutinin disease after rituximab and plasmapheresis.


Journal

Journal of cardiothoracic surgery
ISSN: 1749-8090
Titre abrégé: J Cardiothorac Surg
Pays: England
ID NLM: 101265113

Informations de publication

Date de publication:
10 Oct 2023
Historique:
received: 06 02 2023
accepted: 30 09 2023
medline: 12 10 2023
pubmed: 11 10 2023
entrez: 10 10 2023
Statut: epublish

Résumé

Cold agglutinin disease can lead to significant complications, especially for patients undergoing arch repair requiring hypothermic circulatory arrest. Rituximab and plasmapheresis are treatments for cold agglutinin disease. However, its use in patients with Stanford type A dissection has not been reported. Therefore, after consultation with hematologists, we used rituximab and plasmapheresis before mild hypothermic aortic arch surgery to maintain the body temperature above the thermal altitude. This report describes an 86-year-old male patient with acute type A aortic dissection who received outpatient treatment for rheumatoid arthritis and a 55-mm thoracic aortic aneurysm. The patient was scheduled to undergo urgent surgery for a type A intramural hematoma and progressive aortic aneurysm; however, laboratory test results indicated blood clotting and cold agglutinin. Consequently, urgent surgery was rescheduled. After consulting with hematologists, rituximab was initiated 3 months before surgery, and plasmapheresis was performed 2 days before surgery for cold agglutinin disease. Under mild hypothermia conditions, total arch replacement using the frozen elephant trunk technique was performed while maintaining cerebral and lower body perfusion. The postoperative course was uneventful. On postoperative day 42, the patient was discharged without any neurological deficits. This case involving total arch replacement with mild hypothermia for an aortic arch aneurysm with cold agglutinin disease after rituximab treatment and plasmapheresis resulted in a successful outcome.

Sections du résumé

BACKGROUND BACKGROUND
Cold agglutinin disease can lead to significant complications, especially for patients undergoing arch repair requiring hypothermic circulatory arrest. Rituximab and plasmapheresis are treatments for cold agglutinin disease. However, its use in patients with Stanford type A dissection has not been reported. Therefore, after consultation with hematologists, we used rituximab and plasmapheresis before mild hypothermic aortic arch surgery to maintain the body temperature above the thermal altitude.
CASE PRESENTATION METHODS
This report describes an 86-year-old male patient with acute type A aortic dissection who received outpatient treatment for rheumatoid arthritis and a 55-mm thoracic aortic aneurysm. The patient was scheduled to undergo urgent surgery for a type A intramural hematoma and progressive aortic aneurysm; however, laboratory test results indicated blood clotting and cold agglutinin. Consequently, urgent surgery was rescheduled. After consulting with hematologists, rituximab was initiated 3 months before surgery, and plasmapheresis was performed 2 days before surgery for cold agglutinin disease. Under mild hypothermia conditions, total arch replacement using the frozen elephant trunk technique was performed while maintaining cerebral and lower body perfusion. The postoperative course was uneventful. On postoperative day 42, the patient was discharged without any neurological deficits.
CONCLUSIONS CONCLUSIONS
This case involving total arch replacement with mild hypothermia for an aortic arch aneurysm with cold agglutinin disease after rituximab treatment and plasmapheresis resulted in a successful outcome.

Identifiants

pubmed: 37817219
doi: 10.1186/s13019-023-02388-x
pii: 10.1186/s13019-023-02388-x
pmc: PMC10566192
doi:

Substances chimiques

Rituximab 4F4X42SYQ6

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

281

Informations de copyright

© 2023. BioMed Central Ltd., part of Springer Nature.

Références

Transfusion. 1969 Mar-Apr;9(2):70-3
pubmed: 4975077
Ann Thorac Surg. 2015 Feb;99(2):725-7
pubmed: 25639427
Interact Cardiovasc Thorac Surg. 2015 May;20(5):687
pubmed: 25655279
Anesthesiology. 2004 May;100(5):1151-9
pubmed: 15114212
Immun Ageing. 2020 Nov 20;17(1):38
pubmed: 33292368
Blood Rev. 2020 May;41:100648
pubmed: 31839434
Z Gerontol. 1993 May-Jun;26(3):199-201
pubmed: 8337916
Am J Clin Pathol. 2016 Jun;145(6):789-95
pubmed: 27298398
J Thorac Cardiovasc Surg. 2013 Sep;146(3):668-80
pubmed: 23590925
Ann Thorac Surg. 1995 Oct;60(4):1143-50
pubmed: 7574976
Semin Hematol. 2010 Apr;47(2):187-98
pubmed: 20350666
Haematologica. 2006 Apr;91(4):460-6
pubmed: 16585012
Infusionsther Transfusionsmed. 1993 Apr;20(1-2):19-22
pubmed: 8504237
BMJ Case Rep. 2017 Oct 10;2017:
pubmed: 29021143
J Thorac Dis. 2014 Mar;6 Suppl 1:S60-9
pubmed: 24672700
Blood. 2013 Aug 15;122(7):1114-21
pubmed: 23757733
Anesthesiology. 2004 Oct;101(4):912-7
pubmed: 15448524
Br J Haematol. 2017 Feb;176(3):395-411
pubmed: 28005293
Autoimmun Rev. 2015 Apr;14(4):304-13
pubmed: 25497766

Auteurs

Atsuyuki Mitsuishi (A)

Department of Cardiovascular Surgery Kochi Medical School, 185-1, Kohasu, Nankoku-shi, Okohcho, Kochi Prefecture, 783-8505, Japan. atmitsu@kochi-u.ac.jp.

Yujiro Miura (Y)

Department of Cardiovascular Surgery Kochi Medical School, 185-1, Kohasu, Nankoku-shi, Okohcho, Kochi Prefecture, 783-8505, Japan.

Kyosuke Saeki (K)

Department of Hematology Ehime Prefectural Central Hospital, Matsuyama-shi, Ehime Prefecture, Kasugamachi, 790-0024, 83, Japan.

Yoshinori Nomura (Y)

Department of Clinical Engineering Kochi Medical School, 185-1, Kohasu, Nankoku-shi, Okohcho, Kochi Prefecture, 783-8505, Japan.

Katsumata Yoshifumi (K)

Department of Anesthesiology and intensive Care Medicine Kochi Medical School, 185-1, Kohasu, Nankoku-shi, Okohcho, Kochi Prefecture, 783-8505, Japan.

Keisuke Yoshida (K)

Department of Cardiovascular Surgery Kochi Medical School, 185-1, Kohasu, Nankoku-shi, Okohcho, Kochi Prefecture, 783-8505, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH